Epigenetic modifier alpha-ketoglutarate modulates aberrant gene body methylation and hydroxymethylation marks in diabetic heart
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Epigenetic modifier alpha-ketoglutarate modulates aberrant gene body methylation and hydroxymethylation marks in diabetic heart ; volume:16 ; number:1 ; day:27 ; month:4 ; year:2023 ; pages:1-20 ; date:12.2023
Epigenetics & chromatin ; 16, Heft 1 (27.4.2023), 1-20, 12.2023
- Creator
-
Dhat, Rohini
Mongad, Dattatray
Raji, Sivarupa
Arkat, Silpa
Mahapatra, Nitish R.
Singhal, Nishant
Sitasawad, Sandhya L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13072-023-00489-4
- URN
-
urn:nbn:de:101:1-2023090321025523387041
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dhat, Rohini
- Mongad, Dattatray
- Raji, Sivarupa
- Arkat, Silpa
- Mahapatra, Nitish R.
- Singhal, Nishant
- Sitasawad, Sandhya L.
- SpringerLink (Online service)
Other Objects (12)
Aberrant splicing as potential modifier of the phenotype of junctional epidermolysis bullosa
Aberrant DNA methylation patterns in diabetic nephropathy
Aberrant epigenetic landscape in human pulmonary arterial hypertension
Combined epigenetic/genetic study identified an ALS age of onset modifier
The epigenetic modifier Fam208a is required to maintain epiblast cell fitness
Lineage-specific regulation of epigenetic modifier genes in human liver and brain
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Editorial: Transcriptional and epigenetic regulation in normal and aberrant hematopoiesis
Aberrant epigenetic and transcriptional events associated with breast cancer risk
Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma
Targeting the epigenetic modifier HDAC6 for cancer therapy and for overcoming drug resistance
Aberrant splicing as potential modifier of the phenotype of junctional epidermolysis bullosa
Aberrant DNA methylation patterns in diabetic nephropathy
Aberrant epigenetic landscape in human pulmonary arterial hypertension
Combined epigenetic/genetic study identified an ALS age of onset modifier
The epigenetic modifier Fam208a is required to maintain epiblast cell fitness
Lineage-specific regulation of epigenetic modifier genes in human liver and brain
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Editorial: Transcriptional and epigenetic regulation in normal and aberrant hematopoiesis
Aberrant epigenetic and transcriptional events associated with breast cancer risk
Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma
Targeting the epigenetic modifier HDAC6 for cancer therapy and for overcoming drug resistance
Aberrant splicing as potential modifier of the phenotype of junctional epidermolysis bullosa
Aberrant DNA methylation patterns in diabetic nephropathy
Aberrant epigenetic landscape in human pulmonary arterial hypertension
Combined epigenetic/genetic study identified an ALS age of onset modifier
The epigenetic modifier Fam208a is required to maintain epiblast cell fitness
Lineage-specific regulation of epigenetic modifier genes in human liver and brain
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Editorial: Transcriptional and epigenetic regulation in normal and aberrant hematopoiesis
Aberrant epigenetic and transcriptional events associated with breast cancer risk
Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma